Relmada Therapeutics Inc. (RLMD)

[VictorMasonIsRight]

People suddenly worried about 2.5 million new AUTHORIZED shares?
“don’t worry about dilution, the 2.5 million additional AUTHORIZED shares will probably be ISSUED in a 2.5 million share secondary offering at $75 in 4 months OUTSTANDING!!”

Are you not game for the hunt for the white whale Starbuck ? My fate is sealed

[VictorMasonIsRight]

Correction: Monday the 23rd of April

Moby Dick was predicted to arrive at Bikini on the -new moon- in April, this year that’s Monday the 23rd, if this was an omen then that’s the day RLMD blows

[VictorMasonIsRight]

strange coincidence? sent this text to the Bull of Durham my 40 year chartist buddy after watching Moby Dick for the umpteenth time ( it’s a genetic thing)

“Ahab was a technical chartist, Relmada blows April 22, the full moon, at Bikini!”

Since I wrote the previous strange text I got e mail from my brothers friend whose looking after his estate. I asked him to keep a lookout for an 1830 letter from my great great grandfather to a judge in Boston about being shanghaied on a whaler out of New Bedford
He found it!!! It’s an omen!
Thar she blows!!
April 22 full moon is on next Sunday, do we buy on Friday 18th or Monday the 23rd?

[VictorMasonIsRight]

RLMD long pep talk:

https://https://youtu.be/O5Xu5druM94.be/O5Xu5druM94

I’m riding RLMD like Captain Ahab rode Moby Dick

[VictorMasonIsRight]

“Residual price action. Gap filled. Awaiting a new formation. No call at this point.”
—-Mike, The Bull of Durham trusted chartist
“Important pesky gap, good thing it filled, if it doesn’t hold 33 it’s headed lower, 24 next support”
Under $30 you will be paying less than the financiers of Intel and Apple
No word yet on BTD, effect of BTD widely varied for biotech stocks in the past, muted today in these market conditions
According to Dean Koontz 1981 novel Eyes of Darkness the Wuhan400 man made virus will be released in ‘2020’’
Snopes points out it’s not accurate; Wuhan400 has a shorter incubation period and was 100% fatal.
Thanks Snopes!
Later editions call it the Gorky Virus and put the lab in Russia (?)

https://stockcharts.com/h-sc/ui?s=RLMD
$33 is $10 down from 50 day MAV, $10 up from 200 day
Riding it out like Captain Ahab on Moby Dick

[Paulness]

NEWS -- Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development

NEW YORK, March 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Thomas C. Wessel, M.D., Ph.D., has been appointed the Company's Executive Vice President and Head of Research and Development. Dr. Wessel will lead all clinical development and regulatory activities for Relmada.

Dr. Wessel is a board-certified neurologist with extensive drug development experience, including medical lead for three CNS products approved in the United States: Razadyne®, Lunesta® and Ampyra®. Over the last decade, he served as Chief Medical Officer (CMO) for Acorda Therapeutics, Flex Pharma and more recently at Asceneuron. Dr. Wessel gained extensive experience in the development of CNS active isomers as Senior Vice President of Clinical Research at Sepracor. He also worked on several development projects in neurology and psychiatry at Janssen Pharmaceutical (Johnson & Johnson) in Europe and the United States. Dr. Wessel received his M.D. from the Ludwig-Maximilians-University in Munich, Germany, and his Ph.D. in experimental neurobiology at the Max-Planck-Institute for Psychiatry in Martinsried, Germany. Dr. Wessel completed his residency in neurology at New York Hospital and Memorial Sloan-Kettering Cancer Center (Department of Neurology at Weill Cornell University Hospital) where he remained on the faculty for several years as an Instructor and Assistant Professor before joining the industry.

"Tom's vast CNS drug development expertise will be a significant asset to Relmada as we continue to advance our lead product candidate, REL-1017 (dextromethadone), as an adjunctive treatment in patients with major depression and other potential indications," said Sergio Traversa, Chief Executive Officer of Relmada. "Importantly, he has led the development of three U.S. Food and Drug Administration approved CNS products during his distinguished career. Tom's significant clinical development and regulatory experience, in particular with the development of optical isomers, will be especially critical as we prepare to initiate our pivotal Phase 3 study of REL-1017 as an adjunctive treatment in patients with major depression in the second half of this year. We are excited to add someone with his unique background in CNS to our senior executive management team."

"I am thrilled to join the Relmada team at such a critical time in the Company's corporate evolution," said Dr. Wessel. "Based on the data generated to date, REL-1017 has an extremely compelling product profile and, if approved, could provide an important new treatment option with rapid antidepressant onset for patients who suffer from major depression. I look forward to expanding Relmada's clinical development and regulatory activities and working closely with the academic research community and our team to progress REL-1017 in the clinic towards regulatory approval."

Dr. Ottavio Vitolo, who previously served as Relmada's Chief Medical Officer and Head of Research and Development, has left the company to pursue other opportunities. "Relmada is grateful for Dr. Vitolo's contributions to the Company and wishes him the best of luck in his future endeavors," said Sergio Traversa, CEO of Relmada.

About dextromethadone (REL 1017)

Relmada is currently developing dextromethadone as a rapidly acting oral agent for the treatment of depression. Working as an NMDA receptor antagonist and on the same binding site as ketamine but having shown no ketamine psychotomimetics side effects, dextromethadone is fundamentally differentiated from all currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively. In April 2017, the FDA granted Fast Track designation for dextromethadone for the adjunctive treatment of major depressive disorder.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:

Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://[e-mail]

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-appoints-cns-specialist-thomas-c-wessel-md-phd-as-executive-vice-president-head-of-research-and-development-301019680.html

SOURCE Relmada Therapeutics, Inc.

[Paulness]

NEWS -- Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference

Company Presentation on Thursday, February 27, 2020 at 11:00 AM Eastern Time

NEW YORK, Feb. 25, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference, taking place February 26-27, 2020, in New York City.

Details of Relmada's presentation are as follows:

Presentation Details:

• Date: Thursday, February 27, 2020
• Time: 11:00 AM Eastern Time
• Webcast: http://wsw.com/webcast/svbleerink34/rlmd/

Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact:

Brian Ritchie
LifeSci Advisors
212-915-2578
mailto://[e-mail]

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-9th-annual-svb-leerink-global-healthcare-conference-301010802.html

SOURCE Relmada Therapeutics, Inc.

[VictorMasonIsRight]

Guggenheim hosting RLMD road show DALLAS tomorrow
Boston today,

[VictorMasonIsRight]

@Relmada Therapeutics: A Promising Depression Focused Player For 2020
Feb. 17, 2020 10:08 AM ETRelmada Therapeutics, Inc. (RLMD)AXSM, VTGN2 Comments
Summary

Relmada Therapeutics' lead asset, REL-1017 can be a game-changer in depression indication.
The company has sufficient funds to sustain its operations.
Investors should consider risks such as business concentration risk, R&D failure risk, and commercial uptake uncertainties.

Today, we will study why Relmada Therapeutics (NASDAQ:RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020.”
REL-1017 can offer a more effective yet safer treatment option for TRD patients
In 2017, there were 17.3 million MDD (major depressive disorder) patients in the U.S. Of these, 10% - 30% suffer from TRD (treatment-resistant depression). NMDA antagonists are fast emerging as a potent class of drugs in the depression indication. REL-1017 can prove to be equal or even superior to the much-touted Ketamine with a stronger safety profile as an antidepressant for TRD patients.

....Like Ketamine, D-methadone seems to possess NMDA antagonist properties which have an anti-depressant effect. This was seen in three animal models of depression. The drug's Phase 1 trial also demonstrated a favourable safety and tolerability profile of the drug. D-methadone has not demonstrated adverse events associated with traditional opioid or ketamine at the expected therapeutic doses. D-methadone is an isomer of racemic methadone.

Normally, racemic methadone is associated with common opioid side effects such as anxiety, nervousness, restlessness, sleep problems (insomnia), nausea, vomiting, constipation, diarrhoea, drowsiness, and others. Published literature shows that left or Levo isomer, l-methadone, is largely is related to opioid activity, while the right or Dextro isomer, d-methadone, has less of that activity.



If approved, Dextromethadone may be a more convenient treatment option in terms of its dosing regimen and route of administration.

REL-1017 has demonstrated robust efficacy and safety in Phase 2 trial
On October 15, Relmada Therapeutics announced positive topline data from Phase 2 REL-1017-202, study evaluating two dosages, 25 mg once a day and 50 mg once a day, of REL-1017 as an adjunctive treatment option for TRD patients....

[VictorMasonIsRight]

RLMD very bullish seeking alpha (!) article
Jeffries analyst Tsai excepts 50-100% gain if RLMD receives Breakthrough status.

REL 1017 worth $1-2 billion if approved for TRD alone ($71-$140/share assuming 14mm shares OI&S)

[Biobonic]

And I'm not selling a share.

Opened UGMA accounts for my three grandchildren, all under 4 years old.

Modest start, 200 shares of RLMD (pre reverse split).

Hope to have $50,000 for them when they graduate HS.

[VictorMasonIsRight]

Tiedmann (1.5%) Parsons (2.5%) and VHCP (5.2%) buy chunks of RLMD, soon there won’t be any stock left

[VictorMasonIsRight]

Just don’t know IF RLMD
has applied for BTD or WHEN they may apply, if they haven’t already.
Company doesn’t leak, they should run the NSC

[Biobonic]

From the FDA web
FDA responds within sixty days of receipt of request. Do we know when Relmada made request?
FDA Web
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

To determine whether the improvement over available therapy is substantial is a matter of judgment and depends on both the magnitude of the treatment effect, which could include duration of the effect, and the importance of the observed clinical outcome. In general, the preliminary clinical evidence should show a clear advantage over available therapy.

For purposes of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer to findings that suggest an effect on IMM or serious symptoms, including:

An effect on an established surrogate endpoint
An effect on a surrogate endpoint or intermediate clinical endpoint considered reasonably likely to predict a clinical benefit (i.e., the accelerated approval standard) An effect on a pharmacodynamic biomarker(s) that does not meet criteria for an acceptable surrogate endpoint, but strongly suggests the potential for a clinically meaningful effect on the underlying disease A significantly improved safety profile compared to available therapy (e.g., less dose-limiting toxicity for an oncology agent), with evidence of similar efficacy
A drug that receives Breakthrough Therapy designation is eligible for the following:

All Fast Track designation features Intensive guidance on an efficient drug development program, beginning as early as Phase 1 Organizational commitment involving senior managers
Breakthrough Therapy designation is requested by the drug company. If a sponsor has not requested breakthrough therapy designation, FDA may suggest that the sponsor consider submitting a request if: (1) after reviewing submitted data and information (including preliminary clinical evidence), the Agency thinks the drug development program may meet the criteria for Breakthrough Therapy designation and (2) the remaining drug development program can benefit from the designation.

Ideally, a Breakthrough Therapy designation request should be received by FDA no later than the end-of-phase-2 meetings if any of the features of the designation are to be obtained. Because the primary intent of Breakthrough Therapy designation is to develop evidence needed to support approval as efficiently as possible, FDA does not anticipate that Breakthrough Therapy designation requests will be made after the submission of an original BLA or NDA or a supplement. FDA will respond to Breakthrough Therapy designation requests within sixty days of receipt of the request

[VictorMasonIsRight]

Jeffries wrote Breakthrough Designation could come in ‘1st quarter’
I thought it would be later

[VictorMasonIsRight]

my friend the chartist said it had to back fill to 35-35.5 to resume a strong uptrend, I forgot his warning when it started to run. When will I ever learn to trade?

[VictorMasonIsRight]

Jeffries 41 page buy recommendation today
Now all 3 co managers have published buy reports as expected
After final phase 2 meeting ( first half on 2020) w FDA REL 1017 may get Breakthrough Therapy designation
Watch for large block trades above the offer, whoever it is they haven’t filed a 13D yet
Chart looks like 55-61 short term

[VictorMasonIsRight]

another 100,000 share uptick block ....hmmm

[VictorMasonIsRight]

RLMD 50 day moving average failed to close above 200 day moving average, might take a breather, could resume if FDA grants REL 1017 a ‘breakthrough therapy’, already on Fast Track.

https://stockcharts.com/h-sc/ui?s=RLMD

Not going to sell, ‘expect the unexpected’ -Roald Dahl?
Chartist friend Mike who spotted the strong buy signal at $1.80 (7.20) says it could trade down to support of 351/2 but he's not selling either.
Stronger than expected opening, if there's anything to technical analysis.


?http://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy?

[VictorMasonIsRight]

only reason I wake up at 8:30 is to watch RLMD, today I remembered my sister who got a cross burned in her yard for refunding MLK for a Delta flight he missed, his excuse was pretty good:
“I was in Bull Conner’s jail”

[Biobonic]

Prefer the larger SP of course.

That may be the JNJ low ball offer.

Did they hire Maged Shanouda as CFO just to sell cheap to JNJ?

[VictorMasonIsRight]

Hearing vague rumors about JNJ
I’ve always thought JNJ would buy RLMD, if they paid $100 share it would only be half of what they spent developing Sprovato. Ketamine addiction a big problem in Canada. Just watched a documentary about it.

It makes sense but I hope it doesn’t happen, RLMD will hit 100 on its own this year IMHO, 300-500 once approved

[VictorMasonIsRight]

This chart pattern could improve if it closes above 39.5
Last hour always seems to be the critical time, late lunch? Forgot to enter order?

[VictorMasonIsRight]

This chart pattern is known as the

https://stockcharts.com/h-sc/ui?s=RLMD

‘Leap Out Froggy If You Feel Fit!” Pattern
No, really

[VictorMasonIsRight]

No big pop but that 100,000 share block the other day was an indicator, but it helps
SILICON VALLEY BANK LEERINK only has a $50 short term target but agrees with other revenue projections and profitability estimates, if I’m reading it right 800mm in peak sales with 70% gross margins....huge

[Biobonic]

And you recently added to your share count.

Nice move.

[VictorMasonIsRight]

Relmada Therapeutics (NASDAQ:RLMD) initiated with Outperform rating at SVB Leerink.

[Paulness]

NEWS -- Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer

NEW YORK, Jan. 10, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Maged Shenouda has been appointed the Company's new Chief Financial Officer (CFO). Mr. Shenouda, who has nearly 30 years of biotechnology and equity research experience, has also stepped down from the Company's Board of Directors in order to join the executive management team. Relmada's current CFO, Charles Ence, will assume a new role in the expanded financial team as the Company's Chief Accounting and Compliance Officer.

"We are thrilled that Maged has agreed to join Relmada's senior executive management team as Chief Financial Officer," said Sergio Traversa, Chief Executive Officer of Relmada. "He is an accomplished financial executive in the biotechnology industry, in addition to his significant industry-related experience as an equity research analyst on Wall Street. Maged's substantial financial expertise and deep understanding of the drug development landscape will be critical to Relmada as we continue to develop our lead product candidate, REL-1017 (dextromethadone), as an adjunctive treatment in patients with major depression. We are also extremely pleased that Chuck Ence will continue with Relmada in the key role of Chief Accounting and Compliance Officer in an expanded financial team. With Maged and Chuck together, we believe that we have extremely solid financial operations in place."

"Having served as a Director on Relmada's Board since 2015, I am truly excited by the significant opportunities ahead of the Company, and its potential to help patients with depression and potentially other CNS disorders," said Mr. Shenouda. "I look forward to joining Relmada's operations as Chief Financial Officer and working with an outstanding team as we execute on our corporate development strategy."

"I am excited to continue to serve as an officer of Relmada and add value to the Company's ongoing efforts to succeed and drive shareholder value and importantly, to provide patients with significant opportunities to treat their major depression disorders," said Mr. Ence. "Working with such a dedicated and knowledgeable executive team and a tremendous Board of Directors is truly a personal and professional pleasure."

Most recently, Mr. Shenouda served as CFO and Executive Vice President of Corporate Development for AzurRx BioPharma, a leader in developing non-systemic, recombinant proteins for the treatment of gastrointestinal and infectious diseases. Prior to his tenure at AzurRx, Mr. Shenouda was Senior Vice President and Head of Business Development and Licensing at Retrophin, Inc. Previous to this, Mr. Shenouda spent the bulk of his career on Wall Street as an equity research analyst. He held senior level positions at UBS, JP Morgan and Stifel Nicolaus, covering a broad range of small and large capitalization biotechnology companies. Mr. Shenouda started his sell-side equity research career at Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street, he was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting practice and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories Pharmaceutical Products Division. He earned a B.S. in Pharmacy from St. John's University and is a registered pharmacist in New Jersey and California. He also received an M.B.A from Rutgers Graduate School of Management.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact
Brian Ritchie
LifeSci Advisors
212-915-2578
mailto://[e-mail]

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-strengthens-financial-operations-with-addition-of-maged-shenouda-as-chief-financial-officer-300984881.html

SOURCE Relmada Therapeutics, Inc.

[VictorMasonIsRight]

Forgetting my support line
I bought a little more today, 38.375 that 100,000 share block uptick got my attention.

[VictorMasonIsRight]

Getting down to the support line?

“Three weeks ago it was under $30, they raised $115mm December 4th at $30/share in a secondary offering that was oversubscribed by 4 times pushing it to over $45 briefly... the founding VC of Intel and Apple invested $25mm in 800,000 + shares at $30. Since popping up to $45 it has drifted down slowly to about $40.”
(36 today!)

( 33-35 looks like a line of support technically)

Any news will reverse this steady decline

“It may drift down under $40 in the coming weeks, the chart looks weak short term:

https://stockcharts.com/h-sc/ui?s=RLMD

...but I’m not selling.”

[Biobonic]

Stocktwits

Def: a silly or foolish person.

Aptly named.

[Biobonic]

I am holding and once another binary event occurs in another company,

Am loading up on Relmada.

[VictorMasonIsRight]

“It may drift down under $40 in the coming weeks, the chart looks weak short term:

https://stockcharts.com/h-sc/ui?s=RLMD

but I’m not selling”

- to a guy who sat next to me at the Silverton Town Christmas dinner yesterday, who adjusted my wife’s carburetor on her diesel Mercedes 30 years ago, at 9,318’ it wasn’t moving

Needs a rest, support at 35, since the company doesn’t leak you’ll never know when the next good news is coming

[VictorMasonIsRight]

E mail to a retired airline pilot I sat with at the town Christmas dinner:
Hello XXXX,
Enjoyed meeting you today too. Look forward to going to the Avalanche Brewery.

Are you the St George who got my late wife Gwenn’s Mercedes to run better in the mountains?
image1.jpeg

The biochem company I mentioned is Relmada Therapeutics RLMD on NASDAQ.

Three weeks ago it was under $30, they raised $115mm last week at $30 share in a secondary offering that was oversubscribed by 4 times pushing it to over $45 briefly. Venrock, the founding backers of Intel and Apple, invested $25mm in 800,000 + shares at $30. Since popping up to $45 it has drifted down slowly to about $40.

They since announced two new board members and issued stock options to all the directors at $43.70/ share. One of the new directors Eric Schmidt had previously invested about $380,000 in 55,000 shares ($6 and $9/ share) of the company in two offerings that I participated in last June and in October 2018. He is a PhD (biochem) from MIT was for 20 years a top ranked biotech analyst and banker at Cowan & Co. and currently the CFO of $4b Allogene ( ALLO)

I will forward an email
I recently sent to my veterinarian in Harlingen who treated my cat 9 months ago. I told her about Relmada back ($11) then but none of my e mails got thru to her.

Here are the press releases from the company website:

https://www.relmada.com/news-events/press-releases

It may drift down under $40 in the coming weeks, the chart looks weak short term:

https://stockcharts.com/h-sc/ui?s=RLMD

but I’m not selling.

The company doesn’t leak inside information so I never know when good news is coming. I suspect the next good news will be getting designated a ‘Breakthrough Therapy’ by the FDA (They are already fast tracked by the FDA) or another buy report from some brokerage firm. The first one was published last week by Guggenheim with an initial price target of $64 ( ‘$128 with a 50% certainty’ ) Their long term revenue projection of $1.2 billion supports my estimate of $300-$500/ share.
Let’s get together soon,
Merry Christmas Les



https://www.outtherecolorado.com/mountain-town-fire-takes-out-historic-building-internet-and-cell-service/

[VictorMasonIsRight]

Somebody please tell those stocktwits that these are option awards not yet insider buys
Directors received well deserved options at 43.47

Gueggenheims initial price target is $64 ( $128 w a 50% probability)

...but their peak revenue estimate of $1.2 B for REL-1017 supports my earlier estimate of a $300-$500/share!

Woke up to a huge fire behind the B&B on the 24th, destroyed 2 business but the SVFD and Durango FD
saved the block. They had to fight it all night

[Biobonic]

Ouch...

[VictorMasonIsRight]

Still wondering about the block of 577,000 that traded Friday at the close.

Appeared to be a third market trade typical of Jeffries ( I almost went to work for them in the 80s) Could have been the green shoe getting put away w a fund

Went skiing today for the first time in 49 years, face plant and twisted knee.

[Biobonic]

If the old adage volume before price rings true

RLMD should be heading up as the volume has gone up exponentially since the secondary.

2.8 million shares traded last week alone.

Far cry from a few months ago when 2,800 a day wasn't uncommon.

[VictorMasonIsRight]

Eric Schmidt invested his own money in RLMD
GREAT addition to the board.

[Biobonic]

In regards to the new board members

Would be nice to have VictorMasonWasRight tell us what these men bring to the board.

I'm sure they weren't appointed just to collect some options.

I've added recently.

[Paulness]

NEWS -- Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool


NEW YORK, Dec. 20, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointments of life sciences industry veterans, Eric Schmidt, Ph.D., and John Glasspool, to the Company's Board of Directors, effective December 19, 2019. Dr. Schmidt is currently Chief Financial Officer of Allogene Therapeutics and previously was as a leading Wall Street biotechnology industry analyst for over 20 years. Mr. Glasspool is currently the Chief Executive Officer of Anthos Therapeutics and previously served in multiple senior leadership positions at Novartis and Baxalta.

"We are extremely pleased to welcome Eric and John, both with distinguished careers in the life sciences industry, to our Board," said Sergio Traversa, CEO of Relmada. "Eric brings significant biotech-related financial expertise amassed through his experience as a highly-respected Wall Street biotechnology analyst. John served in increasingly senior leadership roles in various functional areas of corporate management, including commercial operations and corporate strategy, at large life sciences companies. We look forward to their valuable contributions as we continue to advance our lead product candidate, REL-1017 (dextromethadone) as an adjunctive treatment in patients with major depression, for which we recently announced positive top-line results in a Phase 2 study."

Prior to joining Allogene, Dr. Schmidt was Managing Director and Senior Biotechnology Analyst at Cowen and Company. During his two decades there, he was a highly trusted industry analyst whose work was recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters and The Wall Street Journal. Prior to joining Cowen in 1998, Dr. Schmidt was a Vice President and Research Analyst covering the biotechnology sector for UBS Securities. Before joining UBS, he co-founded Cambridge Biological Consultants, a scientific consulting and research firm. Dr. Schmidt holds a B.A. in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology, where he serves on the Visiting Committee for the Department of Biology.

In addition to his role as CEO of Anthos, Mr. Glasspool is a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations, at Baxalta Incorporated, formerly Baxter BioScience. Prior to joining Baxter in August 2012, Mr. Glasspool held positions of increasing responsibility and scope, including Head of Neuroscience Franchise and Head Region Europe – Vaccines & Diagnostics, at Novartis for over 10 years. Earlier in his career, Mr. Glasspool served as Director of Strategic Marketing at Johnson and Johnson.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Investor Contact
Brian Ritchie
LifeSci Advisors
212-915-2578
mailto://[e-mail]

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-strengthens-board-of-directors-with-appointments-of-life-sciences-industry-veterans-eric-schmidt-phd-and-john-glasspool-300978213.html

SOURCE Relmada Therapeutics, Inc.

[The Great Leslie]

Friend from Colorado asked ’dont any of the guys at Venrock own a tie?’
Told him he could buy them all a tie for Christmas from todays bounce

https://www.venrockcp.com/

https://moneyinc.com/most-expensive-neckties/

[The Great Leslie]

Thanks for the analysis
Venrock bought 6.2% of RLMD

https://www.sec.gov/Archives/edgar/data/1553643/000110465919073088/a19-26346_1sc13g.htm

https://www.venrockcp.com/

[Biobonic]

How today's top line results reflect on RLMD and other thoughts

First a bit about SAGE, their drug is NOT an N-methyl-D-aspartate (NMDA) receptor antagonist.

In the top line results for SAGE, by day 42 of the trial 14% drop out in the arm which received the 30 mg dose. By day 42 of the trial 9% drop out in the arm which received the 20mg dose.

These people knew they were receiving the actual trial drug, not the placebo...yet to have 23% drop out before the end of the first segment then another 9% not bother to take the drug on the extended segment of the trial. Doesn't speak well of the drug, imo.

Onto AXSM, the combo of bupropion and DM does produce a slow acting N-methyl-D-aspartate (NMDA) receptor antagonist,

As Relmada's REL-1017 is the same type drug, the positive results of the AXSM trial should be replicated by REL-1017.


And as to patents, I did find this in the latest annual for AXSM:

In 2012, we entered into three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., in which we were granted exclusive licenses to develop, manufacture, and commercialize Antecip’s patents and applications related to the development of AXS-05 and AXS-02...

page 34

There are a number of patents on the AXS-05

As of March 11, 2019, our intellectual property portfolio contains 192 issued patents and more than 165 pending applications in the United States and worldwide. Thirty-one issued United States patents and three issued foreign patents covering our AXS-05 product candidate have claims covering pharmaceutical composition, drug delivery, and pharmacokinetics with protection extending through 2034 for our issued and pending applications.

There is opportunity for all...but I'm a Relmada exclusive.

[The Great Leslie]

My beautiful Wife told me to ‘Load the Boat’, I always did what she told me to do,
made 1100% on 50k invested, I’m getting the seaplane and grandkids will inherit the rest

( don’t know where the ID ‘The Great Leslie’ suddenly popped up, great grandkids call me that, have used Victor Mason )

[TradingBabyishere]

Was alerted here after the first run saying this would be a huge stock and I must say I got some shares with skepticism and it has paid off very nicely.

Can’t complain when it comes to adding another boost to close a very healthy year of profits.

Cheers to all!!!

[The Great Leslie]

Re Guggenheim buy recommendation: Keep in mind $64 is their FIRST price target

IMHO they may think it’s worth $250-500 but they can’t say that at first. I’ve been saying it for 2 years, people thought I was (am) crazy

Next news could be another buy report or designation as a Breakthrough Therapy
Stay on the Yellow Brick Road, Lion

[VictorMasonIsRight]

Another reason I don’t like Nancy, plus her son worked for Burisma


https://www.cnbc.com/2019/12/10/investors-fear-pelosis-drug-price-plan-will-kill-small-biotech-firms.html?__source=iosappshare%7Ccom.apple.UIKit.activity.Message

[VictorMasonIsRight]

Zhiyuan Sun wrote the worst timed report in financial history: predicted RLMD’s Phase 2 would fail
THE DAY BEFORE DATA WAS RELEASED !
His latest article is an attempt to justify this error:

10/17/2019 (Exclusive) Relmada Therapeutics' Financial Hype Is Ill Supported By Its Pipeline Science - Relmada Therapeutics, Inc. (NASDAQ:RLM...
( >>>>!!!!) Short Ideas | Consumer | Editors' Picks
(Exclusive) Relmada Therapeutics' Financial Hype Is Ill Supported By Its
Pipeline Science
Oct. 14, 2019 11:30 AM ET2 comments by: Zhiyuan Sun
Summary
REL-1017's Phase 2a clinical trial is trying to best the clinical profile of Ketamine by attempting to target NMDA receptors without psychotomimetic and/or opiate side effects.
Research has indicated, however, Ketamine cannot exhibit antidepressant effects without dissociative adverse events.
Allergan's Rapastinel, designed to achieve this goal, completely failed to meet its primary endpoints in Phase 3 despite showing promising results in earlier trials.
It is also unlikely REL-1017 can achieve affinity with NMDA receptors without opiate related adverse events when the MOA for Ketamine is highly suspected to be based on opioid agonism.
As its only candidate, Relmada may suffer a devastating decline in its share price in the event of a poor REL-1017 data readout in Q42019.

[VictorMasonIsRight]

Dupe